Early predictive value of bone turnover markers for the changes of bone mineral densities in postmenopausal patients with osteoporosis treated with alendronate
10.3760/cma.j.cn311282-20220320-00167
- VernacularTitle:骨转换指标对阿仑膦酸钠治疗的绝经后骨质疏松症患者骨密度变化的早期预测价值
- Author:
Li SHEN
1
;
Yang XU
;
Zhenlin ZHANG
Author Information
1. 上海交通大学附属第六人民医院临床研究中心 200233
- Keywords:
Alendronate;
Osteoporosis;
Bone mineral density;
Bone turnover markers;
Prediction
- From:
Chinese Journal of Endocrinology and Metabolism
2022;38(7):572-576
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of alendronate treatment and assess the value of bone turnover markers (BTMs) in predicting the changes of bone mineral densities (BMDs) in postmenopausal women with osteoporosis.Methods:In this retrospective study, 409 postmenopausal women with osteoporosis aged (64.86±7.21) years in the Department of Osteoporosis and Bone Disease, Shanghai Sixth People′s Hospital were enrolled from 2012 to 2020. BMDs at lumbar spine 1-4, femoral neck, and total hip, serum β cross-linked C-telopeptide of type 1 collagen (β-CTX), and osteocalcin (OC) were measured before and after treatment.Results:After alendronate treatment for 1 year, BMDs at lumbar spine 1-4, femoral neck and total hip increased 4.84%, 2.13%, and 2.89%, respectively ( P<0.05). At 6 months and 1 year on treatment, β-CTX and OC levels decreased by 77.7%, 42.3% and 78.2%, 49.5%, respectively ( P<0.05). Linear regression analysis showed that for every 10% decrease in the change of β-CTX at 6 months after alendronate treatment, the rate changes in BMDs at the lumbar spine 1-4, femoral neck, and total hip decreased by 0.417%, 0.127%, and 0.213% at 1 year after alendronate treatment; for every 10% decrease in OC, the change rates in BMDs at the lumbar spine 1-4, femoral neck, and total hip decreased by 0.582%, 0.258%, and 0.375%. Conclusions:Alendronate significantly increases BMDs and decreases BTMs levels in elderly women with osteoporosis. BTMs have a predictive value for the changes of BMDs, allowing early monitoring for the effect of alendronate treatment.
